An Open-Label, Randomised, Controlled, Multi-Centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-Old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC or INFANRIX-HEXA [Hib-DTaP-hepatitis B-poliovirus vaccine].

Trial Profile

An Open-Label, Randomised, Controlled, Multi-Centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-Old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC or INFANRIX-HEXA [Hib-DTaP-hepatitis B-poliovirus vaccine].

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary) ; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 17 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top